BE892207A - SLIMMING - Google Patents
SLIMMING Download PDFInfo
- Publication number
- BE892207A BE892207A BE0/207358A BE207358A BE892207A BE 892207 A BE892207 A BE 892207A BE 0/207358 A BE0/207358 A BE 0/207358A BE 207358 A BE207358 A BE 207358A BE 892207 A BE892207 A BE 892207A
- Authority
- BE
- Belgium
- Prior art keywords
- emi
- agent according
- slimming
- slimming agent
- powder
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
- A61K36/708—Rheum (rhubarb)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/886—Aloeaceae (Aloe family), e.g. aloe vera
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Description
Vermageringsmiddel.
De onder_havige uitvinding heeft betrekking
op een vermageringsmiddel met tevens eetlustremmende en
regulerende werkingen.
Het is namelijk bekend dat eetlustremmende
geneesmiddelen zoals diethylpropion (2-diethyl-aminopropio-
fenon) onaangename bijkomstige effecten kunnen vertonen.
Zo kunnen deze geneesmiddelen aanleiding
<EMI ID=1.1>
die de doeltreffende toediening daarvan belemmeren.
Doel van de uitvinding is nu de hierbovenopgesomde nadelen te verhelpen en tevens een algemene regulatie van de levensfuncties te bevorderen.
Dit wordt volgens de uitvinding bereikt door een evenwichtige samenstelling van een eetlustremmende bestanddeel met een daartoe aangepaste regulerende bestanddeel met onder meer laxatieve, kalmerende, anti.depressieve en angstwerende werkingen.
Als eetlustremmend bestanddeel maakt men gebruik van als zodanig bekende geneesmiddelen zoals
<EMI ID=2.1>
(2-diethylaminopropiofenon).
Als regulerend bestanddeel maakt men gebruik van als zodanig bekende geneesmiddelen of ingrediënten zoals Meprobamate (2-methyl-2-propyl-1,3-propaandiol dicarbamaat), vitamine B6 en één of meerdere kruiden zoals rabarber poeder (Rhei pulvis), salie poeder (Salvia pulvis) en aloë poeder (Aloes pulvis).
Al de hierbovengenoemde bestanddelen
kunnen in gewone therapeutische doses in de samenstelling voorkomen. Sommigen kunnen nochtans eveneens in kleinere doses gebruikt worden om reden van de globale werking
van de samenstelling.
De uitvinding wordt nu aan de hand van de hiernavolgende niet beperkende voorbeelden naderhand toegelicht.
VOORBEELD I
De volgende samenstellingen worden toegepast
<EMI ID=3.1>
Elke periode duurt een week lang.
I
Het geneesmiddel wordt 3 maal per dag genomen in poeder-, dragee- of capsule-vorm.
De dosis van bepaalde bestanddelen wordt geleidelijk vergroot. Dit is hier het geval van Phentermine, Diethylpropion, Meprobamate en aloë.
Doordat deze samenstellingen aloë (Aloes pulvis) alsmede een betrekkelijk grotere hoeveelheid rabarber (Rhei pulvis) bevatten, worden hierdoor eerder laxatieve en eetlustremmende werkingen bevorderd.
VOORBEELD II
De volgende samenstellingen worden toegepast
<EMI ID=4.1>
Doordat deze samenstellingen geen aloë
(Aloes pulvis) en een kleinere hoeveelheid rabarber (Rhei pulvis) bevatten wordt hier een regulerend eerder dan een laxatief effect bekomen.
Om de 3 weken mag men tot een sterker type samenstelling overgaan. Men moet steeds beginnen met I.
Andere ingrediënten kunnen eveneens toegepast worden het-zij in vervanging van of in aanvulling tot de hierboven aangeduide produkten.
De uitvinding is bijzonder bestemd voor toepassing met een vermageringsdieet zoals beschreven in aanvrager's dieetboekje "Vermageren en zijn gewicht stabiliseren" verkrijgbaar bij de auteur.
<EMI ID=5.1>
de hierbovengegeven voorbeelden beperkt.
Zo kan Meprobamate worden vervangen door Luminal (fenylethylmalonylureum).
Slimming.
The present invention relates to
on a slimming agent with appetite suppressant and
regulatory actions.
Namely, it is known that appetite suppressant
medicines such as diethylpropion (2-diethyl-aminopropio-
phenon) may show unpleasant side effects.
For example, these drugs can trigger
<EMI ID = 1.1>
hindering its effective administration.
The object of the invention is now to remedy the above-mentioned drawbacks and also to promote a general regulation of the life functions.
This is achieved according to the invention by a balanced composition of an appetite-suppressing ingredient with an adapted regulating ingredient having, inter alia, laxative, calming, anti-depressant and anti-anxiety effects.
As an appetite-suppressing component, use is made of drugs known per se, such as
<EMI ID = 2.1>
(2-diethylaminopropiophenone).
As a regulating ingredient, use is made of drugs known per se or ingredients such as Meprobamate (2-methyl-2-propyl-1,3-propanediol dicarbamate), vitamin B6 and one or more herbs such as rhubarb powder (Rhei pulvis), sage powder ( Salvia pulvis) and aloe powder (Aloes pulvis).
All of the above ingredients
may exist in the composition at ordinary therapeutic doses. Some, however, can also be used in smaller doses for reasons of global action
of the composition.
The invention is now elucidated by means of the following non-limiting examples.
EXAMPLE I
The following formulations are used
<EMI ID = 3.1>
Each period lasts a week.
I
The drug is taken 3 times a day in powder, dragee or capsule form.
The dose of certain ingredients is gradually increased. This is the case here of Phentermine, Diethylpropion, Meprobamate and aloe.
Because these compositions contain aloe (Aloes pulvis) as well as a relatively larger amount of rhubarb (Rhei pulvis), they promote rather laxative and appetite-suppressing effects.
EXAMPLE II
The following formulations are used
<EMI ID = 4.1>
Because these compositions are not aloe
(Aloes pulvis) and a smaller amount of rhubarb (Rhei pulvis) contain a regulative rather than a laxative effect.
Every 3 weeks you can switch to a stronger type of composition. One must always start with I.
Other ingredients may also be used, either in replacement of or in addition to the above products.
The invention is particularly intended for use with a slimming diet as described in applicant's diet booklet "Slimming and Stabilizing His Weight" available from the author.
<EMI ID = 5.1>
the examples given above are limited.
For example, Meprobamate can be replaced by Luminal (phenylethylmalonylurea).
Claims (1)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BE0/207358A BE892207A (en) | 1982-02-19 | 1982-02-19 | SLIMMING |
NL8300546A NL8300546A (en) | 1982-02-19 | 1983-02-14 | Slimming compsns. based on anorexigenic agent - contg. components to counteract side effects |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BE892207 | 1982-02-19 | ||
BE0/207358A BE892207A (en) | 1982-02-19 | 1982-02-19 | SLIMMING |
Publications (1)
Publication Number | Publication Date |
---|---|
BE892207A true BE892207A (en) | 1982-06-16 |
Family
ID=25652999
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BE0/207358A BE892207A (en) | 1982-02-19 | 1982-02-19 | SLIMMING |
Country Status (1)
Country | Link |
---|---|
BE (1) | BE892207A (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0427026A3 (en) * | 1989-10-27 | 1992-04-29 | Indena S.P.A. | Compositions for treating fat deposits in humans |
US5560913A (en) * | 1995-01-27 | 1996-10-01 | The Procter & Gamble Company | Pharmaceutical compositions |
-
1982
- 1982-02-19 BE BE0/207358A patent/BE892207A/en not_active IP Right Cessation
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0427026A3 (en) * | 1989-10-27 | 1992-04-29 | Indena S.P.A. | Compositions for treating fat deposits in humans |
US5560913A (en) * | 1995-01-27 | 1996-10-01 | The Procter & Gamble Company | Pharmaceutical compositions |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR950700056A (en) | Spray-chilled nabumetone | |
RU93051780A (en) | CONTROLLED RELEASE COMPOSITIONS CONTAINING OXYCODONE, METHOD FOR REDUCING DAILY DOSES OF PRODUCTS CONTAINING OXYCODON | |
ATE157257T1 (en) | ENHANCEMENT OF SUPPRESSIVE REGULATION OF AUTOIMMUNE DISEASES BY ORAL OR ENTERAL ADMINISTRATION OF AUTOANTIGENS | |
US20040034083A1 (en) | Combination therapy for the treatment of Parkinson's disease with cyclooxygenase-2 (COX2) inhibitor(s) | |
ATE252899T1 (en) | PRODUCTS CONTAINING THYROID HORMONES | |
BRPI0518266A2 (en) | modified-release oral medicinal product of at least one active ingredient in multi-capsule form | |
JP2013082745A (en) | Anti-inflammatory formulation | |
RU2008119454A (en) | MEDICINE FOR PROTECTION OF MOTOR NEURON IN PATIENTS WITH LATERAL AMYOTROPHIC SCLEROSIS | |
JPS59193821A (en) | Use of fluoxetin as antianxiety | |
JP2004516257A (en) | Compositions and methods for treating diabetic neuropathy | |
Zheng et al. | Gastrodin alleviates bone damage by modulating protein expression and tissue redox state | |
US20070292535A1 (en) | Strontium compositions and methods of treating arthritic and or osteoporitic conditions | |
BE892207A (en) | SLIMMING | |
Tiwari et al. | Radioprotection of plasmid and cellular DNA and Swiss mice by silibinin | |
Jagetia et al. | The evaluation of the radioprotective effect of chyavanaprasha (an ayurvedic rasayana drug) in mice exposed to lethal dose of γ‐radiation: a preliminary study | |
JP2009503072A5 (en) | ||
NL8300546A (en) | Slimming compsns. based on anorexigenic agent - contg. components to counteract side effects | |
Virmani et al. | The possible mechanisms involved in the protection strategies against radiation-induced cellular damage by carnitines | |
JPS5630917A (en) | Preventive and remedy for hepatitis | |
KR920700626A (en) | Drugs for the treatment of toxoplasma disease | |
WO2003101380A2 (en) | Amyotrophic lateral sclerosis treatment with cyclooxygenase-2 inhibitors | |
Ozougwu | Herbal options for the management of drug induced liver damage: A review | |
Azima et al. | The effect of R-1625 (Haloperidol) in mental syndromes: a multiblind study | |
Thakur et al. | The Effects of turmeric on Alzheimer’s patients | |
JP3250630B2 (en) | Anticonvulsants |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RE | Patent lapsed |
Owner name: DE VALCK WILLY Effective date: 19850219 |